A Phase I Trial of B-cell Maturation Antigen (BCMA) Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma (MM)
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Anti-BCMA-CAR-T-Cell-Therapy-Juno-Therapeutics (Primary) ; Cyclophosphamide
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Adverse reactions
- 03 Mar 2017 New trial record.